Why is Medicamen Biotec falling/rising?

As of 10-Jul, Medicamen Biotech Ltd's stock price is currently at Rs 392.90, reflecting a decrease of Rs 1.05, or 0.27%. The stock has been underperforming recently, with a consecutive decline over the last three days, resulting in a total drop of 2.45%. It is also trading lower than its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. The stock is close to its 52-week low, just 4.05% away from Rs 377, and has shown a significant decline of 22.85% year-to-date. Furthermore, the company has reported poor long-term growth, with operating profit decreasing at an annual rate of 16.39% over the past five years, and its return on capital employed (ROCE) is at a low of 5.30%.
In the broader market context, the stock's performance has been notably weaker compared to the benchmark, with a 3-year return of -42.64% against a 52.69% gain in the Sensex. Over the past month, while the Sensex has increased by 0.97%, Medicamen Biotech has declined by 6.47%. This consistent underperformance highlights the challenges the company faces, including falling investor participation, as evidenced by a 34.91% drop in delivery volume against the 5-day average. Despite trading at a discount compared to its peers, the stock's valuation remains expensive, which, combined with its declining net sales and cash reserves, contributes to the negative sentiment surrounding its recent price movements.